Stage‐dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure

Abstract

Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca(2+) handling. Reduction of cytoplasmic Ca(2+) elevated by PDE3 inhibition might decrease this risk of sudden cardiac death.